Research & Development
Otsuka partners with Proteus Digital Health to advance digital medicines in mental health
11 October 2018 -

Japanese healthcare company Otsuka Pharmaceutical Co Ltd revealed on Wednesday the launch of an agreement to expand and strengthen the global collaboration agreement with Proteus Digital Health (Proteus) for the further development and commercialisation of a portfolio of digital medicines for mental health.

The expanded agreement covers the development and commercialisation of digital medicines over the next five years, including the ABILIFY MYCITE (aripiprazole tablets with sensor), which received US FDA's NDA approval in November 2017 for the treatment of schizophrenia, treatment of bipolar I disorder for acute manic and mixed episodes and maintenance therapy and the adjunctive treatment of major depressive disorder.

Under the terms of the expanded collaboration, Otsuka made USD88m in related equity and other payments to Proteus.

As part of the collaboration, a team will be dedicated to commercial development and market coordination for the ABILIFY MYCITE System, software integration and standardisation, manufacturing and supply chain integration, and coordination. This includes the joint development of an expanded portfolio of digital medicines consisting of atypical anti-psychotics used in the treatment of serious mental illness integrated with Proteus sensors.

Both companies will provide new advancements in digital medicine products and care models to address the needs of patients suffering from severe mental illness.



Related Headlines